Comprehensive PGx.
Your medication blueprint. Our broadest pharmacogenetic panel: 29 genes that affect how you process medicines used in cardiology, psychiatry, pain management, oncology, neurology, primary care, gastroenterology, endocrinology, infectious disease and transplant care.
- One sample, no blood draw
- Results in 3–7 business days
- Share with any prescriber
Panel
29 genes
Sample
Saliva or cheek swab
Results
3–7 business days
Price
From $680
What we test
Therapeutic areas covered.
See how your genes may affect your response to certain medications. Review your results with your prescriber.
Heart, blood thinners, cholesterol, blood pressure
VKORC1, CYP2C9, CYP4F2, CYP2C19, SLCO1B1, ABCG2, ADRA2A
Depression, anxiety, ADHD and other psychiatric medications
CYP2D6, CYP2C19, CYP2B6, CYP1A2, COMT, ANKK1, UGT2B15
Pain and anesthesia
CYP2D6, OPRM1, BCHE
Cancer and immunosuppressive therapy
DPYD, TPMT, NUDT15, FCGR3A, CYP3A4, CYP3A5
Diabetes, hormones and metabolism
ATM, CYP2C9, FII, FV, MTHFR
Severe drug-reaction risk and infection
HLA-B*1502, HLA-B*5701, HLA-B*5801, G6PD, CYP2B6 — screening for the variants behind severe reactions to HIV, gout, seizure and mood medications
Who this is for
One report that stays useful as prescriptions change over the years.
Several prescriptions
Cardiology, psychiatry and primary care medications share metabolic pathways — one panel documents them all.
A lifelong baseline
Your genotype does not change. Test once and every future prescriber starts from the same page.
A past severe reaction
The HLA and G6PD screens are designed to catch the variants behind the most dangerous medication reactions.
Is this test right for you?
You take several medications from different specialists.
A medication has caused side effects or failed to work.
You want one report to cover future prescriptions.
A close relative had a severe medication reaction.
Your provider suggested pharmacogenetic testing.
You are about to start a new long-term medication.
Answering yes to even one of these is a good reason to test before the next prescription change.
Before you order
Total price
From $680
One-time price, shown in full at checkout before you pay. No separate fee for the kit, return shipping or the healthcare provider order.
What's included
Kit to report
A saliva or cheek-swab kit with instructions, a prepaid return label, the healthcare provider order, genetic testing in our lab and a gene-drug report in your secure portal.
Who orders the test
A licensed healthcare provider
A licensed healthcare provider in our network reviews your request and places the order during checkout, at no extra cost. No referral needed.
Who reviews the results
A board-certified geneticist
Every report is reviewed and signed in our lab by a board-certified molecular geneticist before it is released.
The science
What the evidence says about getting tested.
Pharmacogenetics has moved from research into routine labeling: hundreds of FDA drug labels now carry genotype-based guidance, and large sequencing studies show that essentially everyone carries at least one clinically actionable pharmacogenetic variant. The question is no longer whether the information exists — it is whether your prescriber has it. A comprehensive panel puts all of it in one report.
99.5%
of people carry at least one clinically actionable pharmacogenetic variant in large sequencing studies.
Source: Pharmacogenomic sequencing studies
200+
of FDA drug labels now include pharmacogenetic information relevant to prescribing.
Source: FDA pharmacogenomic biomarkers table
29
genes on this panel, covering gene-drug pairs with published clinical guidance across ten therapeutic areas.
Source: MyPMC comprehensive panel
Once
test — your genotype never changes, so the report stays valid for every future prescription.
Source: Pharmacogenetics practice guidance
How often should you test?
Test once — your genotype doesn't change. The highest-value moments are before starting a long-term medication, whenever a medication has underperformed or caused side effects, and any time prescriptions change across specialists, since pathways overlap.
Population data
How common is each metabolizer type?
Published population frequencies for the cytochrome P450 enzymes read on this panel. Your report places you in one of these groups for each enzyme.
| Cytochrome | Poor metabolizer | Intermediate metabolizer | Normal metabolizer | Rapid or ultra-rapid metabolizer |
|---|---|---|---|---|
| CYP2D6 | 4–7% | 9–35% | 50–90% | 2–3% |
| CYP2C9 | 3% | 30% | 68% | N/A |
| CYP2C19 | 2–20% | 24–36% | 14–44% | 30% |
Population frequencies compiled from CPIC guidelines and FDA pharmacogenomic biomarker tables; frequencies vary by ancestry.
Clopidogrel — when guidelines say test
ACCF/AHA acute-coronary-syndrome guidance considers CYP2C19 testing case by case, especially after a recurrent event while on clopidogrel. CPIC recommends an alternative antiplatelet when at least one decreased-function CYP2C19 allele is present, and closer bleeding monitoring for increased metabolizers.
Warfarin — genotype-guided dosing
CPIC publishes a dosing algorithm that combines VKORC1 and CYP2C9 genotypes with clinical factors to estimate the safest starting dose, because warfarin's narrow therapeutic window makes trial-and-error dosing risky.
Statins — the SLCO1B1 check
With at least one reduced-function SLCO1B1 allele, CPIC recommends a reduced simvastatin dose or an alternative statin, since higher drug exposure raises the risk of muscle toxicity.
Voriconazole — CPIC dosing guidance
CPIC recommends an alternative agent for CYP2C19 rapid and ultra-rapid metabolizers, because therapeutic levels may never be reached, and for poor metabolizers, because levels climb into the toxic range. The difference matters most in time-critical infections such as invasive aspergillosis.
How widespread is gene-affected prescribing?
More than 250 medicines list pharmacogenomic information in their FDA-approved labeling, and one study estimated 63% of adults and 29% of children with pharmacy coverage had been prescribed at least one gene-affected medication (Liu et al., 2021).
Questions people actually ask
Your medication blueprint, in one report.
One sample, one flat price, a result every future prescriber can refer back to.